GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.

Purpose: Disialoganglioside GD is expressed by glioblastoma multiforme (GBM) cells representing a promising target for anti-GD2 immunotherapeutic approaches. The aim of the present study was to investigate anti-tumor efficacy of the chimeric anti-GD antibody (Ab) dinutuximab beta against GBM.

Methods: Expression levels of GD2 and complement regulatory proteins (CRP; CD46, CD55 and CD59) on well-known and newly established primary tumor originated GBM cell lines were analyzed by flow cytometry.